An Lu

1.1k citations

20 papers · 949 indexed · h-index 10

Impact in

Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Immunology top 10%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in ⓘ

Oncology 18
- CAR-T cell therapy research 16
- Cancer Immunotherapy and Biomarkers 3
Immunology 13
- Immunotherapy and Immune Responses 10
- Immune Cell Function and Interaction 6
- Biosimilars and Bioanalytical Methods 2

Co-authors: Aaron E. Foster (18 shared papers)Cliona M. Rooney (6 shared papers)Malcolm K. Brenner (3 shared papers)Adham S. Bear (2 shared papers)John Craddock (1 shared paper)Martin Pulé (1 shared paper)Mariam Khalil (5 shared papers)Catherine M. Bollard (3 shared papers)
Journals: Blood (5 papers)Journal of Immunotherapy (4 papers)Molecular Therapy (2 papers)Journal of Clinical Oncology (2 papers)Molecular Therapy — Oncolytics (1 paper)
Partner nations: United States Netherlands China

In The Last Decade

An Lu

20 papers receiving 929 citations

Peers

Countries citing papers authored by An Lu

Since Specialization

Citations

This map shows the geographic impact of An Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by An Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites An Lu more than expected).

Fields of papers citing papers by An Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by An Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by An Lu. The network helps show where An Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside An Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with An Lu Line = papers co-authored together An Lu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b Journal of Immunotherapy ·John Craddock, An Lu, Adham S. Bear, Martin Pulé, Malcolm K. Brenner, Cliona M. Rooney, Aaron E. Foster	2010	427
2	Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor Journal of Immunotherapy ·Aaron E. Foster, Gianpietro Dotti, An Lu, Mariam Khalil, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Catherine M. Bollard	2008	175
3	Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40 Molecular Therapy ·Aaron E. Foster, Aruna Mahendravada, Nicholas Shinners, Wei-Chun Chang, Jeannette Crisostomo, An Lu, Mariam Khalil, Éva Morschl, Joanne Shaw, Sunandan Saha, MyLinh T. Duong, Matthew R. Collinson-Pautz, David Torres, Tania Véliz Rodríguez, Tsvetelina Pentcheva‐Hoang, J. Henri Bayle, Kevin M. Slawin, David M. Spencer	2017	93
4	Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches Molecular Therapy — Oncolytics ·MyLinh T. Duong, Matthew R. Collinson-Pautz, Éva Morschl, An Lu, Sławomir Szymański, Ming Zhang, Mary E. Brandt, Wei-Chun Chang, Kelly Sharp, Steven M. Toler, Kevin M. Slawin, Aaron E. Foster, David M. Spencer, J. Henri Bayle	2018	69
5	Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies Leukemia ·Matthew R. Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette Crisostomo, P. Lin, Aruna Mahendravada, Nicholas Shinners, Mary E. Brandt, Ming Zhang, MyLinh T. Duong, J. Henri Bayle, Kevin M. Slawin, David M. Spencer, Aaron E. Foster	2019	64
6	Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma Leukemia & lymphoma ·Jessica A. Shafer, Carolina Colli Cruz, Ann M. Leen, Stephanie Ku, An Lu, Alexandra Rousseau, Helen E. Heslop, Cliona M. Rooney, Catherine M. Bollard, Aaron E. Foster	2010	33
7	Genetic Modification of T Cells With IL-21 Enhances Antigen Presentation and Generation of Central Memory Tumor-specific Cytotoxic T-lymphocytes Journal of Immunotherapy ·Anjum S. Kaka, Donald R. Shaffer, Ryan Hartmeier, Ann M. Leen, An Lu, Adham S. Bear, Cliona M. Rooney, Aaron E. Foster	2009	21
8	In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye Applied Optics ·Aaron E. Foster, Sunkuk Kwon, Ke Shi, An Lu, Karen W. Eldin, Eva M. Sevick‐Muraca, Cliona M. Rooney	2008	18
9	Autologous Designer Antigen-presenting Cells by Gene Modification of T Lymphocyte Blasts With IL-7 and IL-12 Journal of Immunotherapy ·Aaron E. Foster, Ann M. Leen, Timothy Lee, Takayuki Okamura, An Lu, Juan F. Vera, Rachel L. Atkinson, Catherine M. Bollard, Gianpietro Dotti, Cliona M. Rooney	2007	17
10	Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment Journal of Controlled Release ·Weiran Cao, Xue Zhang, Rui Li, Zijie Li, An Lu, F. Richard Yu, Lu Sun, Jiancheng Wang, Zhiyu Wang, Huining He	2024	13
11	Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression Molecular Cancer ·Aaron E. Foster, Fatma Visal Okur, Ettore Biagi, An Lu, Gianpietro Dotti, Eric Yvon, Barbara Savoldo, George Carrum, Michael Andreeff, Margaret A. Goodell, Helen E. Heslop, Malcolm K. Brenner	2009	4
12	Therapeutic Effect of Polaprezinc on Reflux Esophagitis in the Rat Model Digestive Diseases and Sciences ·Wenbo Xie, An Lu, Zhaoyang Liu, Xindi Wang, Xueqi Fu, Junfeng Ma	2023	3
13	Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells Blood ·Aaron E. Foster, MyLinh Duong, An Lu, Peter S. Chang, Aruna Mahendravada, Nicholas Shinners, Kevin M. Slawin, J. Henri Bayle, David M. Spencer	2016	2
14	MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells. Journal of Clinical Oncology ·Aaron E. Foster, Peter S. Chang, Pei‐Yi Lin, Jeannette Crisostomo, Aruna Mahendravada, An Lu, Mariam Khalil, Kevin M. Slawin, David M. Spencer	2015	2
15	Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells Blood ·Aaron E. Foster, Aruna Mahendravada, Nicholas Shinners, Peter S. Chang, An Lu, Éva Morschl, Joanne Shaw, Sunandan Saha, Kevin M. Slawin, David M. Spencer	2015	2
16	Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma Blood ·Tsvetelina Pentcheva‐Hoang, David Torres, Tania Véliz Rodríguez, Ana Korngold, An Lu, Jeannette Crisostomo, Annemarie Moseley, Lorenz Jahn, Mirjam H.M. Heemskerk, Kevin M. Slawin, David M. Spencer, Aaron E. Foster	2016	2
17	Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies Blood ·Joanne Shaw, Xiaoou Zhou, An Lu, Valentina Bertaina, Daria Pagliara, Melissa Aldinger, David M. Spencer, Franco Locatelli, Aaron E. Foster	2018	1
18	Efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch. Journal of Clinical Oncology ·Aaron E. Foster, Jeannette Crisostomo, Peter S. Chang, Pei‐Yi Lin, Aruna Mahendravada, An Lu, Mariam Khalil, Sunandan Saha, Kevin M. Slawin, David M. Spencer	2016	1
19	746. Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy Molecular Therapy ·Tsvetelina P. Hoang, Aaron E. Foster, Tania Véliz Rodríguez, David Torres, An Lu, Jeannette Crisostomo, Lorenz Jahn, Mirjam H.M. Heemskerk, David M. Spencer	2016	1
20	Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma Blood ·Tsvetalina Hoang, Aaron E. Foster, Jeannette Crisostomo, An Lu, Annemarie Moseley, Mirjam H.M. Heemskerk, Kevin M. Slawin, David M. Spencer	2015	1

About An Lu

An Lu is a scholar working on Oncology, Immunology, Gastroenterology, Genetics and Hematology, having authored 20 papers that have together received 949 indexed citations. Recurring topics across this work include CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (10 papers), Immune Cell Function and Interaction (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), Nanowire Synthesis and Applications (2 papers), Virus-based gene therapy research (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and Pancreatic function and diabetes (1 paper). The work is most often cited by research in Oncology (838 citations), Immunology (400 citations), Genetics (298 citations), Biomedical Engineering (323 citations) and Molecular Biology (270 citations). An Lu has collaborated with scholars based in United States, Netherlands and China. Frequent co-authors include Aaron E. Foster, Cliona M. Rooney, Malcolm K. Brenner, Adham S. Bear, John Craddock, Martin Pulé, Mariam Khalil, Catherine M. Bollard, Helen E. Heslop and Gianpietro Dotti. Their work appears in journals such as Blood, Journal of Immunotherapy, Molecular Therapy, Journal of Clinical Oncology and Molecular Therapy — Oncolytics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact